Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $9 pric...
Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target fro...
Truist Securities analyst Asthika Goonewardene reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the pric...
Oppenheimer analyst Matthew Biegler assumes Allogene Therapeutics (NASDAQ:ALLO) with a Outperform rating and lowers Price Ta...
Canaccord Genuity analyst John Newman maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target f...
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate.
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's...
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Insti...
